New serological markers in medical mycology: (1,3)-(-D-glucan and Aspergillus galactomannan  by Ostrosky-Zeichner, Luis et al.
REVISIÓN
New serological markers in medical mycology:  
(1,3)-β-D-glucan and Aspergillus galactomannan
Luis Ostrosky-Zeichnera,*, Roxana G. Vitaleb and Marcio Nuccic
aDivision of Infectious Diseases, University of Texas Medical School, Houston, Texas, United States
bLaboratorio de Micologia, Unidad de Parasitología, Hospital JM Ramos Mejía, CABA, Buenos Aires, Argentina
cUniversity Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
* Corresponding author. 
Division of Infectious Diseases 
University of Texas Medical School at Houston 
6431 Fannin, MSB 2.112 - Houston, TX 77030, USA 
Voice: (713) 500-6733; Fax: (713) 500-5495 
E-mail: Luis.Ostrosky-Zeichner@uth.tmc.edu (L. Ostrosky-Zeichner) 
 
0123-9392/$ - see front matter © 2012 ACIN. Publicado por Elsevier España, S.L. Todos los derechos reservados.
Infectio
Asociación Colombiana de Infectología
www.elsevier.es/infectio
Infectio. 2012;16(Supl 3): 59-63
Abstract
Invasive fungal infections present a great challenge in modern medicine. The recent devel-
opment of serologic markers represents a clear advance in the field. Two serological tests 
have been developed: (1,3)-β-D glucan and Aspergillus galactomannan. This review discusses 
highlights of both tests.
© 2012 ACIN. Published by Elsevier España, S.L. All rights reserved.
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Microscopía estereoscópica: Se observan cabezuelas de Aspergillus spp cultivado en caja de Petri.
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Nuevos marcadores serológicos en micología médica: (1,3)-βD-glucanos y 
galactomanano de Aspergillus
Resumen
Las infecciones invasoras por hongos representan un gran reto para la medicina moderna. El 
reciente desarrollo de marcadores serológicos representa un claro avance en este campo. Se 
han desarrollados dos pruebas serológicas: (1,3) - β-d-glucano y galactomanano de Aspergillus. 
Esta revisión recoge los aspectos más destacados de cada una de las pruebas.
© 2012 ACIN. Publicado por Elsevier España, S.L. Todos los derechos reservados.
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Introduction
Invasive fungal infections (IFI) present a great challenge in 
modern medicine. Due to the expansion of the population 
of immunosuppressed patients worldwide, the incidence of 
IFI has greatly increased, with high morbidity and mortal-
ity. One of the key elements for improving the outcome of 
IFI is the early initiation of appropriate antifungal treat-
ment, which can be accomplished by the early diagnosis 
such infections. The problem is that the diagnosis of IFI 
is difficult, with non-specific and subtle clinical manifes-
tations, and poor sensitivity of culture-based diagnostic 
tools1.
The recent development of serological markers rep-
resents a clear advance in the field. While cryptococcal 
antigen is the standard of care for the diagnosis and man-
agement of cryptococcosis, until recently there were no 
serological tests to help in the diagnosis of important IFIs, 
such as invasive aspergillosis and candidiasis. Two sero-
logical tests have been developed: (1,3)-β-D glucan (BG) 
and Aspergillus galactomannan. This review will discuss 
highlights of both tests.
(1,3)-β-D-glucan
(1,3)-β-D glucan is an important structural component of 
the majority of fungal cell walls2. Fungi that are known 
to have higher concentrations of BG in their cell walls 
include Candida, Saccharomyces, Trichosporon, Spo-
rothrix, Penicillium, Fusarium, and Aspergillus. In gen-
eral terms, molds such as Scedosporium and the agents 
of mucormycosis tend to have lower concentrations. Of 
note, Cryptoccocus neoformans has relatively low levels 
of this substance, and data are sparse for agents of the 
endemic mycoses, such as Histoplasma, Coccidioides, and 
Blastomyces3. As an almost pan-fungal marker, research-
ers have developed assays that are able to detect this 
complex carbohydrate in serum and variety of other flu-
ids, such as bronchio-alveolar lavage fluid, cerebrospinal 
fluid, and abscess fluid4,5.
The majority of assays are constructed as enzymatic/
colorimetric methods based on the fact that BG triggers 
the coagulation cascade of the amebocyte cells of the 
horseshoe crab (Tachypleus in Asia and Limulus in North 
America) through the factor G pathway. It is also impor-
tant to consider that amebocyte lysates from the different 
crab species have different affinity to BG, resulting in dif-
ferent cut-off values for different assays. Therefore it is 
very important to consider the specific kit and region of 
the world where it is made when interpreting results, as 
well as the related literature6. Other assays not relying on 
coagulation have been described, but have not undergone 
robust or large-scale validation.
It is widely considered that BG results represent active 
infection and are not affected by fungal colonization7. 
Antifungal therapy has not shown to interfere with the 
diagnostic performance of the assay either8. BG may 
be present in the bloodstream from a variety of other 
sources, such as surgical gauze, blood products, and fil-
tered intravenous medications. It is important to consider 
such factors when interpreting results.
(1,3)-β-glucan D as a panfungal diagnostic 
marker
Much of the initial validation of BG as diagnostic marker 
was carried out in Japan, where early studies reported 
high sensitivity and specificity in hospitalized patients with 
fever and fungal infection9. The first multicenter evalua-
tion in North America was published in 2005, reporting that 
the sensitivity and specificity of the assay were 69.9% and 
87.1%, respectively8. This study also showed that results 
were not affected by antifungal therapy. More recently, 
Karageorgopoulos et al.6 performed a meta-analysis on 2979 
patients from 16 large scale cohort and case-control studies 
assessing the diagnostic performance of BG, and reported a 
pooled sensitivity of 76.8% and specificity of 85.3%. Sensitiv-
ity was similar both for Candida and Aspergillus. BG is now 
considered alternative microbiological evidence of fungal 
infection in the latest version of the European Organization 
for Treatment and Research of Cancer/Mycosis Study Group 
criteria for diagnosis of fungal infection10.
(1,3)-β-D glucan as an outcome or  
prognosis assessment tool
Beyond diagnosis, where the Karageorgopoulos study 
established the final performance characteristics of the 
BG assay, attention has now been focused on the correla-
tion of BG levels with outcomes and prognosis. Koo et al.11 
showed that BG tends to decline in patients with invasive 
candidiasis, aspergillosis and pneumocystosis, but failed to 
show prognostic value. In a cohort of patients with inva-
sive candidiasis with an heterogeneous antifungal therapy 
background, Sims et al.12 showed again that BG levels tend 
to decrease in successfully treated patients and increase in 
treatment failures. More recently, Jaijakul et al.13 showed 
that in a large cohort of patients with invasive candidiasis 
treated with an echinocandin followed by an azole, the 
slope of a curve constructed with BG values correlated 
well with the treatment outcome. Furthermore, in that 
study a cut-off of <416pg/ml predicted a positive outcome 
with a positive predictive value of 89%.
Although evidence is accumulating for the use of BG for 
these purposes, this approach is still considered experi-
mental and has not been endorsed by any guidelines.
Incorporating (1,3)-β-D glucan into new  
management strategies for invasive fungal 
infections
Aside from the obvious diagnostic and prognostic applica-
tions of BG, and considering the limitations of current 
diagnostic techniques and the evidence that delayed diag-
nosis and treatment increase mortality, research is now 
focusing on incorporating BG monitoring as part of an early 
or “pre-emptive” treatment approach.
In a proof of concept study, Takesue et al.14 followed 
a cohort of liver transplant recipients, following BG levels 
periodically and giving antifungal therapy when patients 
were febrile. In a retrospective analysis, they showed 
that patients who had positive BG results had a higher 
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likelihood of their fever responding to fluconazole. In 
a randomized pilot study, Hanson et al.15 showed that 
patients randomized to receive anidulafungin triggered 
by positive BG results during twice weekly surveillance 
received antifungals more frequently than those who 
received it empirically or for a positive culture. The anti-
fungal was well tolerated and there were numerically 
less proven and probable fungal infections, although the 
difference was not significant due to the sample size. 
More recently, Ostrosky-Zeichner et al. conducted a multi-
center, randomized, placebo-controlled trial of caspofun-
gin prophylaxis in high risk ICU patients (clinicaltrials.gov 
#NCT00520234). The study incorporated BG measurements 
twice weekly as a way to identify prophylaxis failures 
early and allowed for caspofungin to be used in an open 
label fashion on those patients, becoming functionally a 
pre-emptive therapy study nested in the main prophylaxis 
trial. The authors showed that the BG-based pre-emptive 
therapy strategy decreased the incidence of proven and 
probable invasive candidiasis cases.
Although exciting advances have been done in this area, 
further research is required to assess the efficacy of these 
types of interventions on major patient and economic out-
comes.
Galactomannan
Invasive aspergillosis (IA) has become an important cause 
of death in patients under risk, such as those suffering from 
hematological malignancies, those undergoing hematopoietic 
cell transplantation, and solid organ transplant recipients 
(especially of the lung)16. Galactomannan (GM) is a polysac-
charide released by growing Aspergillus hyphae that can be 
measured in the serum and other body fluids. The Platelia® 
Aspergillus EIA is a one stage immunoenzymatic sandwich 
microplate assay which detects circulating GM from body fluids 
(mainly serum and bronchoalveolar lavage). It uses rat EBA-2 
monoclonal antibodies which are directed against Aspergillus 
galactomannan. The result is expressed as an index.
Galactomannan in the serum to early  
diagnose invasive aspergillosis
The serum galactomannan index assay (GMI) has been widely 
used for the diagnosis of IA, with an excellent performance 
in neutropenic patients with hematological malignancies 
or in the pre-engraftment phase post-hematopoietic cell 
transplantation. The sensitivity of the test in patients not 
receiving antifungal therapy was reported as 87.5%17. In 
another study, the sensitivity and specificity of the GM test 
was shown to be 96.8% and 82.4%, respectively18. The best 
use of GMI in this setting is as a screening method to early 
diagnose IA or to trigger the initiation of antifungal therapy 
(diagnostic-driven or preemptive antifungal therapy). A typi-
cal protocol for early diagnosis or screening is to perform the 
test three times per week. The easiest way of using GMI in 
this context is to rely on its high negative predictive value 
and rule out IA when the test is repeatedly negative. How-
ever, one must be alert to the fact that false-negative tests 
may occur when the patient is receiving an anti-mold anti-
fungal agent19. Another important cause of false-negative 
test is if the patient is no longer neutropenic. Therefore, if 
the patient is neutropenic and is not receiving an anti-mold 
antifungal agent, repeatedly negative GMI is good at ruling 
out IA. On the other hand, once a patient develops one posi-
tive test (defined when the index value in serum is =>0.5) 
additional measures are made according to the pre-test 
probability of IA. In this context, the clinician should rely 
on a curve rather than on just a single test. Because animal 
models have consistently shown a sharp relationship between 
serum GMI and fungal burden in tissue20, the best interpreta-
tion for an ascending GMI curve is that the patient is devel-
oping IA. In such circumstance, additional tests are ordered, 
including chest and sinuses computed tomography. Indeed, 
we described a form of early IA in patients with multiple 
myeloma in which patients had host factors, clinical features 
and mycological criteria for IA, but lacked the typical (and 
later) images of well-circumscribed lesions, air crescent or 
cavity on chest CT21. Instead, those patients had non-specific 
infiltrates (patchy, ground-glass, tree in bud) that eventually 
evolved to specific well-circumscribed lung infiltrates. A sim-
ilar observation was made later by other authors in patients 
with acute myeloid leukemia, patients with lymphoprolifera-
tive diseases, and in allogeneic hematopoietic cell transplan-
tation recipients with graft versus host disease22.
A consequence of the early diagnosis of IA is that the out-
come is improved because the disease is being treated with a 
low fungal burden in the same way that the outcome of neo-
plastic diseases is better the lower the tumor burden.
Galactomannan in the serum to monitor  
treatment of invasive aspergillosis
Treatment response in IA has relied on composite response 
criteria that take into account improvement in clinical find-
ings and imaging. The problem is that symptoms are non-
specific and radiological images frequently worsen during 
the course of treatment of IA, including when neutrophils 
recover, creating an inflammatory immune reconstitution 
syndrome23. Specifically, currently accepted criteria define 
response with a specific percentage of reduction in the 
volume of infiltrates. However, the reliability and repro-
ducibility of such readings are greatly imprecise. On the 
other hand, GMI trends down early in the course of disease, 
when patients are responding to treatment, and its kinet-
ics may be very useful to predict the outcome. We recently 
compared the European Organization for Treatment and 
Research of Cancer/Mycosis Study Group response criteria 
with criteria based on the kinetics of GMI. We defined suc-
cess as survival plus repeatedly negative serum GMI for ≥2 
weeks after the first negative GMI in the absence of new 
extra-pulmonary IA lesions and failure as a persistently posi-
tive serum GMI. Death within the 14 day-period was consid-
ered as failure, unless autopsy examination failed to reveal 
IA. Among 115 patients with IA, agreement was observed 
in 91% of cases, with 100% agreement in failure and 87% 
in success24. More recently, we reported that normaliza-
tion of GMI within 7 days from the first positive test was 
strongly associated with the outcome25. Therefore, a simple 
and objective serum biomarker may be useful to monitor 
therapy as early as seven days after diagnosis.
62 L.Ostrosky-Zeichner et al
Galactomannan in the serum in  
non-neutropenic patients
While GMI is very useful in neutropenic patients (as dis-
cussed earlier), its value in non-neutropenic patients is less 
certain. In one study the sensitivity of GMI was 23.1% and 
the specificity was 76.1%, with a positive predictive value 
of 1.6% only, but a negative predictive value of 98.3%26. In 
non-neutropenic patients false-negative results are more 
frequent. Therefore, the best use of GMI is when results of 
sequential tests trend up. In this setting, every attempt to 
confirm the diagnosis of IA should be advanced.
False positive results
Several possible causes of false-positive reactions have 
been described, among which the direct interaction of 
some antibiotics with the Platelia Aspergillus test has 
been recently highlighted. Such cross-reactivities have 
been found mainly for some β-lactams but not for other 
commonly used antibiotics of fungal origin (penicillins and 
cephalosporins), non-fungal origin (erythromycin, gen-
tamicin, and vancomycin), and synthetic origin (quinolo-
nes). The clinical relevance of this cause of false-positive 
results has been recently challenged27. It is important to 
note that GM is a complex sugar also found in many food 
products. In addition, lipoteichoic acid from the bacterium 
Bifidobacterium may also cross-react with the assay, and 
false-positive results may occur owing to high bacterial 
loads of Bifidobacterium in the gut of pediatric patients28. 
In addition, other fungi may cross-react for the GMI test. 
These include Fusarium, Histoplasma capsulatum, Alter-
naria, Penicillium and Paecylomyces29.
Galactomannan detection in bronchoalveolar 
lavage
Detection of GMI in the bronchoalveolar lavage (BAL) has 
become a very important tool for the diagnosis of IA. Sev-
eral studies have been performed in order to evaluate the 
usefulness of this assay and the more appropriate cut-off 
index. In one study in 128 patients with hematological dis-
eases and pulmonary infiltrates, GMI in the BAL performed 
better than conventional methods for the microbiological 
diagnosis of IA, both in neutropenic and non-neutropenic 
hematology patients30. The sensitivity of BAL GMI (at a 
cut-off of ≥1.0) was 91.3%, compared with 50% and 53% 
for culture and direct examination, respectively. In 20 
patients GMI positivity was the only microbiological ﬁnding 
for IA on BAL samples. Conversely, negative BAL GMI ruled 
out IA with a very high negative predictive value (96%, 
at a cut-off of ≥1.0). A sensitivity of almost 97% was also 
observed in 31 proven IA with a cut-off for positivity of 
≥1. This high sensitivity was consistent with other reports 
in hematology patients31, in solid-organ transplant recipi-
ents32, and non-immunocompromised patients (all using 
the ≥1 cut-off), and in critically ill neutropenic patients 
(using the≥ 0.5 cut-off)33,34. In a more recent study, the 
performance of GM in BAL in patients at risk was per-
formed, and evaluated by using a range of index cut-offs 
to define positivity. Using a BAL fluid GM index of ≥0.8 the 
sensitivity in diagnosing proven and probable IA was 86.4%, 
and the specificity was 90.7%. At this cut-off, the positive 
and negative predictive values were 81% and 93.6% respec-
tively. An OD index value ≥3.0 corresponded to 100% spe-
cificity, and an OD index cut-off of <0.5 corresponded to 
a high sensitivity, virtually always ruling the disease out. 
For all values in between, the probability of IPA depends 
largely on other factors35.
In the case of IA in lung transplant recipients, it was 
observed that using an index value of 0.5 for the serum, GM 
detection in BAL had a sensitivity of 60% and a specificity 
of 95%. The specificity increased to 98% when the index 
cut-off value of 1 was used, while the sensitivity remained 
the same36. In another study the positive predictive value 
of a positive BAL GM test was low at the 0.5 cut-off (24.2%). 
However, the increase in the specificity improved without 
compromising sensitivity. The best cut-off was defined at 
1.5 (sensitivity 100% and specificity 90.4%)37.
Conclusions
Galactomannan assay is a useful tool for detection of IA in 
patients at high risk. The cut-off value in serum was ≥ 0.5, 
and in BAL the best cut-off was ≥ 1.5. Serum GMI helps 
to early diagnose and monitor IA therapy  in neutropenic 
patients.
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